A Phase 3 interventional study of VSA003 and Placebo in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by Visirna Therapeutics HK Limited. Active, not recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Visirna Therapeutics HK Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.
Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 8th registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 12–55
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 12+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5
First in 2001; this study’s year is marked. 1 started in 2024.
This study's enrollment of 46 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 20 across the 11 interventional studies, 5 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
Visirna Therapeutics HK Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Visirna Therapeutics HK Limited has 1 study filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Homozygous Familial Hypercholesterolemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125847First Affiliated Hospital Xi'an Jiaotong UniversityNGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia | 2027-03-30 |
| NCT07591298CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia | 2027-09-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and LDL-C in subjects with persistent dyslipidemia. In this clinical study, the efficacy and safety of VSA003, an RNAi-based therapeutic targeting ANGPTL3, will be evaluated in subjects with HoFH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous injections
Drug: VSA003
subcutaneous injections
Drug: Placebo
subcutaneous injections
Also known as: AROANG3, Zodasiran
subcutaneous injections
Percent change from baseline in serum LDL-C at month 6
Time frame: At month 6
Percent change and absolute change in serum ANGPTL3 levels from baseline at month 6
Time frame: At month 6
Percent change and absolute change in serum LDL-C, ApoB, non-HDL-C, VLDL-C, TC and TG levels from baseline
Time frame: Up to month 6, Up to month 18
Percent change and absolute change in serum HDL-C, ApoC-III, ApoC-II, ApoA-I, ApoA-V and Lp[a] levels from baseline
Time frame: Up to month 6, Up to month 18
Percentage of patients achieving ≥30% reduction in serum LDL-C from baseline
Time frame: At month 6, At month 18
Percentage of patients achieving ≥50% reduction in serum LDL-C from baseline
Time frame: At month 6, At month 18
Number of Participants with Adverse Events
Time frame: Up to month 6, Up to month 18
Number of Participants with Anti-Drug Antibodies (ADAs) to VSA003 Over Time
Time frame: Up to month 6, Up to month 18
Correlation between VSA003 serum concentrations and QT intervals
Time frame: Up to month 6, Up to month 18
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Dec 2025, 13 months.
Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Homozygous Familial Hypercholesterolemia →
Visirna Therapeutics HK Limited